TPD Drug Discovery Resources
Links to a range of publicly available resources to assist in drug discovery from target identification, molecule optimisation and competitor landscaping
Targeted Protein Degradation (TPD) company directory
Also now including other Induced Proximity & Bifunctional Therapeutics-Focused Companies - now at 80 and still growing
Have only included companies whose main or only focus is TPD or bifunctional molecule development. There is a lot of great TPD work going on within pharma but that is specifically excluded from this list
- 76Bio
- https://www.76bio.com/
- Next gen TPD but few details yet...
- https://www.76bio.com/
- A-Alpha Bio
- https://www.aalphabio.com/
- Expanding synthetic biology platform into glue discovery based on huge PPI database from nearly 1Bn datapoints using yeast fusion screening
- https://www.aalphabio.com/
- Accutar Biotech
- https://www.accutarbio.com/
- Multiple potential best in class PROTACs for targets like AR, ER, BTK now in clinic
- https://www.accutarbio.com/
- Adhesion Therapeutics (formerly Celeris)
- https://adhesiontx.com/
- Machine learning-driven glue design
- https://adhesiontx.com/
- Ambagon Therapeutics
- https://www.ambagontx.com/
- 14-3-3-based molecular glues
- https://www.ambagontx.com/
- Amphista Therapeutics
- https://amphista.com/
- New degrading mechanisms with advantages over CRBN, VHL etc
- https://amphista.com/
- Apertor Pharmaceuticals
- https://apertorpharma.com/
- Using modified bacterial macrocycles as glues to induce proximity across a wide range of proteins
- https://apertorpharma.com/
- Arvinas
- https://www.arvinas.com/
- The first dedicated TPD biotech with the most advanced assets in PhIII
- https://www.arvinas.com/
- Asha Therapeutics
- https://www.ashatherapeutics.com/
- De novo drug design using PRISM (Proximity-inducing small molecules) platform applied to inhibitors, glues and other protein degraders though few specifics
- https://www.ashatherapeutics.com/
- AUTOTAC Bio
- http://autotacbio.com/
- Korea-based autophagy-based company recruiting p62 receptor into AUTOTACs. Check out Dr Kwon's video on the web site.
- http://autotacbio.com/
- Automera
- https://automeratx.com/
- Singapore-based autophagy start-up with their own (undisclosed) take on AUTAC design
- https://automeratx.com/
- Avilar Therapeutics
- https://avilar-tx.com/
- Extracellular degraders
- https://avilar-tx.com/
- Biohaven Therapeutics
- https://www.biohaven.com/
- Pre-clinical work on ASGPR-based bivalent degraders (MoDE platform targeting eg IgG or IgA) and antibody-recruiting cytotoxics (ARM platform) including former work from Kleo Pharmaceuticals
- https://www.biohaven.com/
- BioTheryx
- https://www.biotheryx.com/
- PROTACs & glues
- https://www.biotheryx.com/
- Booster Therapeutics
- https://www.boostertx.com/
- Using degraders to affect cellular homeostasis & senescence
- https://www.boostertx.com/
- C4 Therapeutics
- https://c4therapeutics.com/
- Early CRBN PROTAC & glue company now with multiple clinical programmes
- https://c4therapeutics.com/
- Captor Therapeutics
- https://captortherapeutics.com/
- Poland-based glue & PROTAC company
- https://captortherapeutics.com/
- Casma Therapeutics
- https://www.casmatx.com/
- Autophagy-based degraders
- https://www.casmatx.com/
- Cullgen
- https://www.cullgen.com/
- Now clinical phase PROTAC/glue company known for innovating around new degrading mechanisms
- https://www.cullgen.com/
- Dialectic Therapeutics
- https://www.dtsciences.com/
- Single asset company with DT2216 in clinic as a VHL-based, platelet-sparing Bcl-xL degrader with claimed improved window over thrombocytopenia relative to Bcl-xL inhibitors like venetoclax due to low VHL expression in platelets
- https://www.dtsciences.com/
- Degron Therapeutics
- https://www.degrontx.com/
- Shanghai-based with usual glue approaches to GSPT1 & Wee1
- https://www.degrontx.com/
- Differentiated Therapeutics
- https://www.dxtherapeutics.com/
- Molecular dynamics and other computational approaches to find new TPD agents
- https://www.dxtherapeutics.com/
- DraupnirBio
- https://draupnir.bio/
- Degradation of extracellular proteins using a new lysosomal degradation mechanism
- https://draupnir.bio/
- Dunad Therapeutics
- https://www.dunadtx.com/
- New monovalent inhibitors and degraders using covalent expertise from the labs of founder Pat Gunning
- https://www.dunadtx.com/
- EntactBio
- https://entactbio.com/
- Komander, Urbe, Buhrlage et al spinout Inducing proximity to deubiquitinases to trim Ub chains to induce protein stabilisation, signalling etc
- https://entactbio.com/
- EpiBiologics
- https://www.epibiologics.com/
- Bispecific antibody-based degraders of extracellular and membrane-associated targets
- https://www.epibiologics.com/
- f5 Therapeutics
- https://www.f5therapeutics.com/
- Molecular glues for novel targets using phenotypic screening approaches
- https://www.f5therapeutics.com/
- Fimecs
- https://www.fimecs.com/en/
- PROTACs, initially for pseudokinases - acquired by RaQualia Pharma Feb 2024
- https://www.fimecs.com/en/
- FireflyBio
- https://fireflybiologics.com/
- From the Versant team who bought you Mone Rosa comes another ADC meets TPD biotech with Nobelist Carolyn B on board - what's not to love?
- https://fireflybiologics.com/
- Foghorn Therapeutics
- https://foghorntx.com/
- Range of glues and PROTACs directed to targets in chromatin regulation, now in clinical phase
- https://foghorntx.com/
- Frontier Medicines
- https://www.frontiermeds.com/
- E3 ligase work but now moving away from TPD as central strategy
- https://www.frontiermeds.com/
- Gandeeva Therapeutics
- https://gandeeva.com/
- The usual mix of AI to give new glues through proprietary means but with an added dose of cryo-EM to assist in optimisation
- https://gandeeva.com/
- GluBio Therapeutics
- https://www.glubiotx.com/
- Clinical phase glue compnay based out of China/San Diego with IKZF1/3 & CK1a assets now in clinic
- https://www.glubiotx.com/
- GlycoEra
- https://www.glycoera.com/
- Extracellular degrader company using bifunctional glycosylated biologics (G-LyTACs) to direct to lysosomal degradation
- https://www.glycoera.com/
- Halda Therapeutics
- https://haldatx.com/
- Not TPD but another "CrewsCo" with an unusual take on tying up essential proteins selectively in tumor cells to kill them using RIPTACs
- https://haldatx.com/
- Haisco Pharmaceutical Group
- https://en.haisco.com/
- Pharma with established pipeline with foray into BTK PROTAC now in clinic
- https://en.haisco.com/
- Hinova Pharmaceutical
- https://www.hinovapharma.com/en/
- Extensive pipeline with several PROTACs now including AR in clinic
- https://www.hinovapharma.com/en/
- Indupro Therapeutics
- https://www.induprotx.com/
- Bispecific agents inducing proximity including VHH-based agents targeting membrane E3 (REULR)
- https://www.induprotx.com/
- Kesmalea Therapeutics
- https://kesmalea.com/
- Unique chemistry platform to generate new degrading drugs overcoming problems of first generation agents
- https://kesmalea.com/
- Kintor Pharmaceutical
- https://en.kintor.com.cn/
- Dermatology & oncology with topical AR PROTAC in clinic and other degrader programmes
- https://en.kintor.com.cn/
- Kymera
- https://www.kymeratx.com/
- Established clinical phase PROTAC company showing progress outside oncology through immunology pipeline
- https://www.kymeratx.com/
- Laigo Bio
- https://www.laigobio.com/en/
- From the labs of Madelon Maurice, using bispecific antibodies termed SureTACs to harness membrane-associated E3 ligases for degradation of cell surface substrates
- https://www.laigobio.com/en/
- Lycia
- https://lyciatx.com/
- Lysosomal degrader company using LYTACs from Nobelist Carolyn Bertozzi
- https://lyciatx.com/
- Lyterian
- https://lyterian.com/
- Recent entrant to protein homeostasis founded by great team including Ingrid Wertz & Miche Rape
- https://lyterian.com/
- Magnet Biomedicines
- https://magnetbio.com/
- Rockstar glue company founded by Schreiber, Cravatt et al promising rational glue discovery using their TrueGlue platform
- https://magnetbio.com/
- Monte Rosa
- https://www.monterosatx.com/
- Claimed rational glue design with lead GSPT1 degrader now in clinic
- https://www.monterosatx.com/
- Neomorph
- https://neomorph.com/index.html#home
- Glue company with pioneering scientists form Celgene & Novartis group
- https://neomorph.com/index.html#home
- NeoX
- https://www.neoxbio.com/index_en.html
- Computational platform to design new bifunctional degraders (NeoDegraders) of BTK etc
- https://www.neoxbio.com/index_en.html
- Nested Therapeutics
- https://nestedtx.com/
- Now in clinic with lead asset NST-628, a non-degrading molecular glue which sticks MEK to different RAF isoforms thus inhibiting MAPK signalling with broad anti-tumor effects.
- https://nestedtx.com/
- Nurix
- https://www.nurixtx.com/
- BTK degrader franchise but E3 inhibitors and now DACs as well
- https://www.nurixtx.com/
- Oerth.bio
- https://www.oerthbio.com/
- Joint venture between Arvinas & Bayer to apply TPD methods to agri applications though presumably will need ultra high potency to keep cost of good down and won't be spraying IMiD derivatives on fields?
- https://www.oerthbio.com/
- Orionis Biosciences
- https://orionisbio.com/
- Mainly cytokine-based therapies but expanding into glues in partnership with pharma
- https://orionisbio.com/
- Origami Therapeutics
- https://origamitherapeutics.com/
- Claim to have platform able to identify protein stabilizers and degraders though are setting sights high by focusing on CNS targets
- https://origamitherapeutics.com/
- Orum Therapeutics
- https://www.orumrx.com/
- Leading degrader-antibody conjugate company using mainly GSPT1 glue conjugates also in protein stabilisation via E3 inhibitors
- https://www.orumrx.com/
- Outrun Therapeutics
- https://outruntx.com/
- April 2024 spinout from Satpal Virdee at Dundee aims to inhibit specific E3 ligases for selective protein stabilization
- https://outruntx.com/
- Paq Therapeutics
- https://www.paqtx.com/
- Autophagy-based degradation using ATTECs (Autophagasome-tethering compounds)
- https://www.paqtx.com/
- Phoremost
- https://www.phoremost.com/
- New E3 binder discovery using peptide scanning libraries though TPD pipeline early
- https://www.phoremost.com/
- Photys
- https://www.photys.com/
- Introducing the concept of Phosphorylation-Inducing Chimeric Small Molecules (PHICS)
- https://www.photys.com/
- Pin Therapeutics
- https://www.pintherapeutics.com/eng/main/main.html
- Searching for new E3 ligases for glue & PROTAC discovery
- https://www.pintherapeutics.com/eng/main/main.html
- Plexium
- https://www.plexium.com/
- Glue and monovalent degrader discovery across many programmes
- https://www.plexium.com/
- Progenra
- https://progenra.com/
- PROTAC and glue company now pivoted to focus on Parkinson's Disease via Parkin/PINK axis
- https://progenra.com/
- Proteovant
- https://proteovant.com/ - now acquired by SK Biopharmaceuticals
- Former TPD-focused Vant from the Roivant family previously advancing the Oncopia TPD pipeline from Shaomeng Wang
- https://proteovant.com/ - now acquired by SK Biopharmaceuticals
- Proxidrugs
- https://www.proxidrugs.de/
- Not a biotech as such but a cluster of German universities, led out of Frankfurt, focused on therpaeutic application of TPD
- https://www.proxidrugs.de/
- Proxygen
- https://proxygen.com/
- Rational glue discovery from Austria with leading academics as founders./advisors
- https://proxygen.com/
- Ranok Therapeutics
- https://www.ranoktherapeutics.com/
- Enigmatic TPD company advancing unique chaperone-recruiting mechanism to degrade protein with claimed tumor-specific effects. Now in clinic - unique mechanism throws up many opportunities and questions.
- https://www.ranoktherapeutics.com/
- Rapafusyn Pharmaceuticals
- https://www.rapafusyn.com/
- Use analogs of rapamycin to find non-degrading glues as ligands for difficult to drug targets
- https://www.rapafusyn.com/
- Salarius Pharmaceuticals
- https://salariuspharma.com/
- Cereblon-based glues of well-known targets but using modified chemistry with deuterium-based platform
- https://salariuspharma.com/
- Seed Therapeutics
- https://seedtherapeutics.com/
- Lilly-founded molecular glue company with lead RBM39 asset nearing clinic
- https://seedtherapeutics.com/
- Sibylla Biotech
- https://www.sibyllabiotech.it/
- A novel protein degradation strategy from Italy acting on folding intermediates rather than mature protein. Interesting.
- https://www.sibyllabiotech.it/
- Siduma Therapeutics
- https://www.sidumathera.com/
- Still stealthy but led by Craig Crews and some of the original Arvinas crowd so expect to see some interesting bifunctional-based efficacy - or maybe not this time. Closed April 2024
- https://www.sidumathera.com/
- Solu Therapeutics
- https://solutherapeutics.com/
- Modulating the immune system by bifunctional antibody-recruiting CyTaCs (Cytotoxicity Targeting Chimera) using a nice approach spun out of GSK
- https://solutherapeutics.com/
- Stablix
- https://www.stablix.com/
- Recruiting deubiquitinases to stabilize proteins in the antithesis to PROTACs. Likely to be useful for many loss of function disorders if as flexible as TPD
- https://www.stablix.com/
- SyntheX
- https://www.synthexlabs.com/
- Machine learning to find glues to specific E3 ligases. 2022 deal with BMS who know a thing or two about glue discovery.
- https://www.synthexlabs.com/
- Ternarx
- https://www.wehi.edu.au/business-development-and-ventures/success-stories/ternarx/
- Melbourne, Australia-based TPD company with Bekky Feltham & David Komander amongst founders/advisors promising to tackle undruggable transcription factors using new TPD approaches
- https://www.wehi.edu.au/business-development-and-ventures/success-stories/ternarx/
- Triana Biosciences
- https://trianabio.com/
- Industrializing glue discovery
- https://trianabio.com/
- Ubiquigent
- https://www.ubiquigent.com/
- Combination of DUB inhibitors and degraders as well as DUBTACs as well - truly DUB-omics
- https://www.ubiquigent.com/
- Ubix
- http://www.ubixtrx.com/
- PROTACs, glues and ADCs against well known targets now in clinic
- http://www.ubixtrx.com/
- Uppthera
- https://www.uppthera.com/
- Korean TPD Co with lead PLK1 PROTAC approaching clinic
- https://www.uppthera.com/
- Venquis
- https://venquistx.com/
- Monovalent degraders. Not glues. Not PROTACs. MoA not clear yet
- https://venquistx.com/
- Vicinitas
- https://vicinitas.com/
- Dan Nomura-founded stabilizer company using DUBTACs by recruiting deubiquitinases
- https://vicinitas.com/
- Civetta, Cedilla, Polyprox (no longer trading)
NB Monovalent degraders are often called molecular glues, MonoDACs, CELMods, NEXMods etc
Bifunctional degraders were initially known as PROTACs but this is now a trademarked term (by Arvinas) so proteolysis-targeting chimeras may be known as BiDACs, Proximity-Inducing Compounds etc
I will call bifunctional degraders PROTAC(TM)s here and acknowledge Arvinas' trademark
For a directory of upcoming TPD conferences, please click here
TPD Drug Discovery Resources
- Want to know everything about the localisaton of your drug target of choice? Head over to the Human Protein Atlas
- A concise summary of a wealth of CRISPR & RNAi screens is held at DepMap. There's a shiny app visualisation to help show targets required for tumor cell proliferation or cell essentiality.
- For a record of most active and complete clinical studies, please visit Clinicaltrials.gov
- See the great range of resources collated by Chris Swain at Cambridge Med Chem Consulting for help on everything from hit identification through to lead optimisation and candidate selection
- For commentary on recent important literature in the TPD space, take a look at the CeTPD Journal Club, run by members of Alessio Ciulli's team from the Centre for TPD at the University of Dundee
- Some good links to cheat sheets and other general drug discovery info can be found from DrugHunter here
- More resources being added all the time - check back soon
© 2023-2024
All rights reserved. Janus Drug Discovery Consulting Ltd
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.